Survival After Cancer Diagnosis in Persons With AIDS

Biggar, Robert J.; Engels, Eric A.; Ly, Sonny; Kahn, Amy R.; Schymura, Maria J.; Sackoff, Judith; Virgo, Phillip; Pfeiffer, Ruth M.

doi:10.1097/01.qai.0000164033.02947.e3

Cited by 124 publications

(131 citation statements)

References 11 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Short and mid-term survival probabilities for these malignancies, among our patients, were similar to those observed in other cohorts of HIV-infected subjects. 8,30,31 On the other hand, despite the post-HAART increase in overall survival, the survival of our patients with some malignancies was shorter than that observed in the general population. 32 EUROCARE-4 32 was a large-scale study that investigated long-term survival among European general population with different types of cancer.…”

Section: Discussionmentioning

confidence: 58%

“…The use of HAART improved short-and medium-term survival in HIV-infected patients with cancer, 8 especially those with ADM [13][14][15] and some types of NADM (e.g., HD) 16,17 and reduced the difference from the general population. 8 However, very few studies described 10-year survival in patients with HIV and cancer, and the only published data are limited to subjects with NHL, Kaposi's sarcoma (KS), and anal cancer.…”

mentioning

confidence: 99%

“…10 These findings may be attributable both to specific cancer characteristics in HIV-infected individuals (a more aggressive behavior and an advanced stage at diagnosis) [6][7][8]11,12 and to subject characteristics (immunodeficiency, low performance status). The use of HAART improved short-and medium-term survival in HIV-infected patients with cancer, 8 especially those with ADM [13][14][15] and some types of NADM (e.g., HD) 16,17 and reduced the difference from the general population. 8 However, very few studies described 10-year survival in patients with HIV and cancer, and the only published data are limited to subjects with NHL, Kaposi's sarcoma (KS), and anal cancer.…”

mentioning

confidence: 99%

“…3,4 Short or mid-term survival (5 years) among HIVinfected patients with AIDS-defining malignancies (ADM) or non-AIDS-defining malignancies (NADM) has been extensively investigated. In the pre-HAART era, the prognosis of patients with HIV-infection and cancer was significantly poorer than that of uninfected subjects with cancer [5][6][7][8] : the overall 2-year survival of patients with non-Hodgkin's lymphoma (NHL) was only 15% 8 against a survival probability greater than 60% in the general population, 9,10 and the 2-year survival of Hodgkin's disease (HD) did not reach 35% 8 compared to a proportion greater than 85% in the general population. 10 These findings may be attributable both to specific cancer characteristics in HIV-infected individuals (a more aggressive behavior and an advanced stage at diagnosis) [6][7][8]11,12 and to subject characteristics (immunodeficiency, low performance status).…”

mentioning

confidence: 99%

“…In the pre-HAART era, the prognosis of patients with HIV-infection and cancer was significantly poorer than that of uninfected subjects with cancer [5][6][7][8] : the overall 2-year survival of patients with non-Hodgkin's lymphoma (NHL) was only 15% 8 against a survival probability greater than 60% in the general population, 9,10 and the 2-year survival of Hodgkin's disease (HD) did not reach 35% 8 compared to a proportion greater than 85% in the general population. 10 These findings may be attributable both to specific cancer characteristics in HIV-infected individuals (a more aggressive behavior and an advanced stage at diagnosis) [6][7][8]11,12 and to subject characteristics (immunodeficiency, low performance status). The use of HAART improved short-and medium-term survival in HIV-infected patients with cancer, 8 especially those with ADM [13][14][15] and some types of NADM (e.g., HD) 16,17 and reduced the difference from the general population.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies

Spagnuolo

Galli

Salpietro

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

Few data are available regarding the 10‐year survival among subjects with HIV and cancer. The aim of this study was to evaluate the 10‐year survival of HIV‐infected subjects with AIDS‐defining malignancies (ADM) or non‐AIDS‐defining malignancies (NADM). This was a single center, retrospective, observational study of subjects with HIV infection and a subsequent cancer diagnosis; the data were collected from January 1991 to April 2010. Malignancies were divided into ADM or NADM on the basis of the Centre of Diseases Control‐1993 classification. Survival curves were estimated using Kaplan–Meyer method and compared by the log‐rank test. Six hundred and fifteen (9.5%) of the 6,495 subjects recorded in the San Raffaele Infectious Diseases Database developed a malignancy: 431 (70%) an ADM and 184 (30%) a NADM. In the case of ADM, survival was more favorable when cancer was diagnosed during post‐highly active antiretroviral therapy (HAART) era (10‐year survival: 43.2% ± 4.4%) than when diagnosed during the pre‐HAART era (10‐year survival: 16.4% ± 2.7%; log‐rank test: p < 0.001). The same was true in the case of NADM (10‐year survival: 44.7% ± 5.5% vs. 33.3 ± 9.6%; log‐rank test: p = 0.03). An evaluation of survival probability by cancer type showed higher survival rates during the post‐HAART era in the case of non‐Hodgkin lymphoma (10‐year survival: 42.1% ± 5.3% vs. 11.4% ± 3.3%; log‐rank test: p = <0.001), Kaposi's sarcoma (10‐year survival: 44.0% ± 8.4% vs. 23.5% ± 3.9%; log‐rank test: p < 0.001) and Hodgkin's disease (10‐year survival: 49.5% ± 14.5% vs. 40.0% ± 12.7%; log‐rank test: p = 0.005). Despite the better cancer prognosis during the post‐HAART era, the 10‐year survival of HIV‐infected subjects with an ADM or NADM is poor.

show abstract

Section: Discussionmentioning

confidence: 58%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies

Spagnuolo

Galli

Salpietro

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

Neoplasms in People Living with Human Immunodeficiency Virus

Wang¹,

Chiao²

2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

People living with human immunodeficiency viruses (PLWH) are at increased risk for developing malignancies, particularly virally mediated cancers such as Kaposi sarcoma (KS), some types of lymphoma, and HPV‐related cancers, such as cervical cancer and anal cancer. PLWH also have higher rates of alcohol and tobacco use, which increases their risk of non‐virally mediated cancers, such as lung cancer and both oropharyngeal and non‐oropharyngeal head and neck cancers. KS and lymphomas tend to occur at lower CD4 counts, and the incidences of these cancers have decreased since the advent of effective combination antiretroviral therapy (ART). However, the incidence for virally mediated cancers (such as anal cancer) other non‐virally‐mediated non‐acquired immunodeficiency syndrome‐defining cancers (such as lung cancer) have risen in the past decade in part because PLWH are living longer with wide‐spread access to ART. In the past, PLWH with cancers often had lower survival and poorer outcomes due to severe immunodeficiency and poor performance status. In the modern ART era, survival and outcomes for individuals with human immunodeficiency virus (HIV)‐associated lymphomas are generally similar to the HIV‐negative population using standard rituximab‐based multi‐agent chemotherapy. For PLWH with other solid tumors, standard of care treatment is also currently recommended. Active areas of research for cancers in PLWH includes cancer prevention, immunotherapy, and continued development of new therapeutics to improve outcomes.

show abstract